<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2016.52004</article-id><article-id pub-id-type="publisher-id">PI-17466</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20160200000_12269320.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  精神分裂症治疗相关靶点及药物研究进展
  Receptors and Related Drug Development for Schizophrenia: Research Advances
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贾</surname><given-names>晓凤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>中国药科大学，江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>04</month><year>2016</year></pub-date><volume>05</volume><issue>02</issue><fpage>19</fpage><lpage>24</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   精神分裂症是一种慢性致残性精神障碍。由于发病早、病程长、发病率高且病情严重，精神分裂症给社会带来沉重的经济负担。目前对精神分裂症的治疗主要使用典型和非典型抗精神分裂症药物。然而典型抗精神分裂症药物仅对阳性症状有效且同时还伴有严重的锥体外系不良反，非典型抗精神分裂症药物虽然对阴性症状和认知障碍有一定改善作用且锥体外系不良反发生率显著降低，但却又出现其他不良反应。因此，需要开发更为安全有效的抗精神分裂症药物。近年来研究发现，与抗精神分裂症药物开发相关的靶点包括多巴胺受体、5-HT受体、Glu受体、大麻受体和sigma受体等。本文对与精神分裂症相关的靶点及药物研究进展进行综述。&lt;br/&gt;Schizophrenia is a chronic disabling mental disorder. Because of its severity, chronicity, early age of onset, and prevalence, schizophrenia is the source of enormous human and economic costs. At present, schizophrenia is treated with typical and atypical antipsychotics. However, typical anti-psychotics are effective only in treating positive symptoms, and they may result in extrapyramidal side-effects. Although atypical antipsychotics have a certain improvement in negative symptoms and cognitive impairment and do not produce the extrapyramidal side-effects, there are other side effects. Therefore, we need more effective and safer antipsychotics. Recent studies found that those receptors associated with schizophrenia, such as dopamine receptor, 5-hydroxytryptamine receptor, glutamate receptor, cannabinoid receptor, sigma receptor and so on. This review summarizes the receptors and relevant drug development associated with Schizophrenia in recent years. 
  
 
</p></abstract><kwd-group><kwd>精神分裂症，药物治疗，靶点, Schizophrenia</kwd><kwd> Treatment Drugs</kwd><kwd> Receptors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>精神分裂症治疗相关靶点及药物研究进展<sup> </sup></title><p>贾晓凤，何玲<sup>*</sup></p><p>中国药科大学，江苏 南京</p><disp-formula id="hanspub.17466-formula212"><graphic xlink:href="http://html.hanspub.org/file/3-1710068x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年4月2日；录用日期：2016年4月26日；发布日期：2016年4月29日</p><disp-formula id="hanspub.17466-formula213"><graphic xlink:href="http://html.hanspub.org/file/3-1710068x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>精神分裂症是一种慢性致残性精神障碍。由于发病早、病程长、发病率高且病情严重，精神分裂症给社会带来沉重的经济负担。目前对精神分裂症的治疗主要使用典型和非典型抗精神分裂症药物。然而典型抗精神分裂症药物仅对阳性症状有效且同时还伴有严重的锥体外系不良反，非典型抗精神分裂症药物虽然对阴性症状和认知障碍有一定改善作用且锥体外系不良反发生率显著降低，但却又出现其他不良反应。因此，需要开发更为安全有效的抗精神分裂症药物。近年来研究发现，与抗精神分裂症药物开发相关的靶点包括多巴胺受体、5-HT受体、Glu受体、大麻受体和sigma受体等。本文对与精神分裂症相关的靶点及药物研究进展进行综述。</p><p>关键词 :精神分裂症，药物治疗，靶点</p><disp-formula id="hanspub.17466-formula214"><graphic xlink:href="http://html.hanspub.org/file/3-1710068x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>精神分裂症(schizophrenia)是一种慢性致残性精神障碍，多起病于青壮年, 全球患病率接近1% [<xref ref-type="bibr" rid="hanspub.17466-ref1">1</xref>] 。常见表现为幻觉妄想、行为紊乱等阳性症状，情感淡漠、意志行为退缩等阴性症状，注意力、执行能力、记忆能力减退等认知功能障碍。自1911年被E. Bleule提出至今，经过一个世纪的研究，仍然病因未明。目前认为精神分裂症发病机制与神经递质功能异常及遗传和环境因素等有关，主要的理论学说有：神经发育障碍；多巴胺功能亢进；谷氨酸功能紊乱；5-羟色胺学说等。但没有一种学说能够全面地解释精神分裂症的发病机制。这给抗精神分裂症药物的研究开发带来不便。本文对与精神分裂症治疗相关的靶点及药物研究进展进行综述。</p></sec><sec id="s4"><title>2. 多巴胺受体</title><p>多巴胺(Dopamine, DA)受体属G蛋白偶联受体家族，有5种亚型。D<sub>1</sub>受体家族包括D<sub>1</sub>和D<sub>5</sub>受体，通过G蛋白激活腺苷环化酶活性。D<sub>2</sub>受体家族包括D<sub>2</sub>、D<sub>3</sub>和D<sub>4</sub>受体，通过G蛋白抑制腺苷环化酶活性。D<sub>1</sub>和D<sub>2</sub>类受体分别与锥体外系运动调节、情感情绪、精神理智及垂体前叶内分泌调节有关。大量研究表明，精神分裂症的发病、治疗及预后都与多巴胺受体密切相关。</p><sec id="s4_1"><title>2.1. 1D2受体拮抗剂</title><p>典型抗精神分裂症药物如氯丙嗪、氟哌啶醇，通过拮抗中枢DA D2受体，阻断DA能神经元突触前后D<sub>2</sub>受体，从而降低DA神经系统的功能，对阳性症状具有明显疗效。但对阴性症状和认知障碍无改善作用甚至能使其加重 [<xref ref-type="bibr" rid="hanspub.17466-ref2">2</xref>] 。由于其对背侧与腹侧纹状体神经元上的D<sub>2</sub>受体无选择性，导致锥体外系反应(Extrapyramidal Side-effects，EPS)，迟发型运动障碍(Tardive Dyskinesia, TD)等不良反应发生率高，影像学研究表明当药物与D<sub>2</sub>受体的亲和力 ≥80%时，EPS明显增加。故典型抗精神分裂症药物的应用受到限制。</p></sec><sec id="s4_2"><title>2.2. 选择性D2/D3受体拮抗剂</title><p>非典型抗精神分裂症药物氨磺必利 [<xref ref-type="bibr" rid="hanspub.17466-ref3">3</xref>] 对中枢DA D<sub>2</sub>/D<sub>3</sub>受体有较高的亲和力，对D<sub>3</sub>受体的亲和力是D<sub>2</sub>受体的2倍，而对D<sub>1</sub>、D<sub>4</sub>及D<sub>5</sub>受体几乎无亲和力，对5-HT受体、胆碱能受体、α肾上腺素受体和组胺H<sub>1</sub>受体等均不具有亲和力，对精神分裂症的阳性症状、阴性症状和认知障碍均有较好的改善作用。氨磺必利对中脑边缘叶作用较强，而对纹状体作用不明显，且与其他受体几乎无亲和力，故较少产生EPS。</p></sec><sec id="s4_3"><title>2.3. D<sub>2</sub>/5-HT受体拮抗剂</title><p>非典型抗精神分裂症药物利培酮、齐拉西酮均是5-HT和DA受体拮抗剂，对5-HT<sub>2A</sub>/DA D<sub>2</sub>受体亲和力高，此外还有弱α<sub>1</sub>和H<sub>1</sub>受体拮抗作用。对精神分裂症阳性、阴性症状及认知障碍均有较好疗效。齐拉西酮对阴性症状疗效更好，且不会引起血清泌乳素水平升高和体重增加。</p></sec><sec id="s4_4"><title>2.4. 非选择性D2受体部分激动剂</title><p>D<sub>2</sub>受体部分激动剂可使DA能神经递质恢复至正常水平并维持恒定，但研究表明仅部分激动D<sub>2</sub>受体的化合物并没有明显抗精神分裂症的效应。阿立哌唑为D<sub>2/3/4</sub>受体和5-HT<sub>1A</sub>受体的部分激动剂 [<xref ref-type="bibr" rid="hanspub.17466-ref4">4</xref>] ，同时亦是5-HT<sub>2A/2C</sub>受体的拮抗剂 [<xref ref-type="bibr" rid="hanspub.17466-ref5">5</xref>] ，临床疗效与5-HT<sub>2</sub>/D<sub>2</sub>受体拮抗剂利培酮相当，但不良反应发生率比利培酮低 [<xref ref-type="bibr" rid="hanspub.17466-ref6">6</xref>] 。2015年，美国FDA批准的抗精神分裂症新药 [<xref ref-type="bibr" rid="hanspub.17466-ref7">7</xref>] ：①月桂酰阿立哌唑(aripiprazole lauroxil)，是阿立哌唑的前药，肌肉注射后经酶水解转变成N-羟甲基阿立哌唑，再水解转变成阿立哌唑而发挥作用。不良反应，静坐不能；②卡利拉嗪(cariprazine)，是一种多巴胺D<sub>3</sub>/D<sub>2</sub>和5-HT<sub>1A</sub>受体部分激动药，同时对5-HT<sub>2A</sub>受体具有拮抗作用，其对D<sub>3</sub>受体的亲和力约是D<sub>2</sub>受体的10倍。卡利拉嗪对DA D<sub>3</sub>R的高选择性可能是其副作用少的原因，用于精神分裂症治疗时的不良反应有震颤、发晕及肌张力障碍 [<xref ref-type="bibr" rid="hanspub.17466-ref8">8</xref>] 。③依匹哌唑(brexpiprazole)，研究表明其治疗效果可能是部分激动5-HT<sub>1A</sub>和多巴胺D2受体，拮抗5-HT<sub>2A</sub>受体，具体机制不详。不良反应有体重增加，静坐不能。以上提示只有D<sub>2</sub>受体部分激动剂在其他受体(如5-HT受体和DA受体的其他亚型)上也有作用靶点时才能产生较为理想的抗精神分裂症效果。</p></sec></sec><sec id="s5"><title>3. 5-羟色胺受体</title><p>5-羟色胺(5-hydroxytryptamine, 5-HT)受体亦属G蛋白偶联受体家族。共有7大类，14个亚型。在调节睡眠、体温和精神、情绪等中枢功能方面有重要作用。中枢神经系统5-HT含量及功能异常可导致多种精神类疾病。研究表明，与精神分裂症相关的5-HT受体有5-HT<sub>1A</sub>、5-HT<sub>2</sub>、5-HT<sub>6</sub>受体 [<xref ref-type="bibr" rid="hanspub.17466-ref9">9</xref>] 。临床前研究表明，5-HT<sub>1A</sub>受体部分激动剂坦度螺酮(tandospirone)，能增强低剂量氟哌啶醇的作用，特别是对认知障碍的改善 [<xref ref-type="bibr" rid="hanspub.17466-ref10">10</xref>] 。5-HT<sub>2</sub>受体拮抗剂依利色林，高选择性5-HT<sub>2A</sub>受体拮抗剂M100907，在临床试验中均显示出介于阳性药氟哌啶醇组和安慰剂组之间的疗效，但M100907对以阴性症状为主的患者并没有明显疗效 [<xref ref-type="bibr" rid="hanspub.17466-ref11">11</xref>] 。5-HT<sub>6</sub>受体选择性拮抗剂SB271046能够改善精神分裂症患者的认知障碍 [<xref ref-type="bibr" rid="hanspub.17466-ref12">12</xref>] 。因而仅作用于5-HT受体并不能获得理想的抗精神分裂症疗效。而DA受体结合5-HT受体的研究已显示出喜人的前景。尤其是2015年FDA批准的3种抗精神分裂症新药，更预示未来抗精神分裂症新药研究开发的方向：多巴胺受体与5-羟色胺受体拮抗或部分激动剂。</p></sec><sec id="s6"><title>4. 其他与抗精神分裂症药物研发相关的受体靶点</title><sec id="s6_1"><title>4.1. 谷氨酸受体</title><p>谷氨酸受体分成两大类：离子型谷氨酸受体(ionotropic Glutamate Receptor, iGluR)和代谢型谷氨酸受体(metabotropic Glutamate Receptor, mGluR)。iGluR根据与激动剂的选择性又分为N-甲基-D-天冬氨酸(N-Methyl-D-Aspartate, NMDA)、α-氨基羧甲基恶唑丙酸(α-Amino-3-hydroxy-5-Methylisoxozol-4-Propionate, AMPA)、海人藻酸(Kainate, KA)3个亚型，介导快信号传导。mGluR属于G蛋白偶联受体家族，共有8个亚型。按照其氨基酸序列和在不同的信号激活通路中的作用分为3组：第一组包括mGluR<sub>1</sub>和mGluR<sub>5</sub>，激活磷脂酸C，产生cAMP并释放花生四烯酸；第二组包括mGluR<sub>2</sub>和mGluR<sub>3</sub>，第三组包括mGluR<sub>4</sub>、mGluR<sub>6</sub>、mGluR<sub>7</sub>、mGluR<sub>8</sub>。第二、三组则抑制腺苷酸环化酶活性。</p><p>NMDA受体在突触的可塑性上起关键作用，与学习、记忆等密切相关。易化NMDA受体可能有改善精神分裂症的作用。临床实验已证实NMDA受体甘氨酸(Glycine, Gly)位点的激动剂Gly、丝氨酸(Serine, Ser)或D-环丝氨酸(D-cycloserine)可作为治疗精神分裂症的辅助剂 [<xref ref-type="bibr" rid="hanspub.17466-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.17466-ref14">14</xref>] 。LY2140023是美国Eli Lilly公司开发的代谢型谷氨酸受体2/3(mGluR2/3)激动剂，II期临床试验结果显示LY2140023虽在减少患者阳性症状方面不如奥氮平，但其疗效仍达到了显著改善程度。更重要的是，LY2140023没有出现奥氮平用药所致的体重增加明显现象 [<xref ref-type="bibr" rid="hanspub.17466-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.17466-ref16">16</xref>] 。ADX63365是Merck与Addex公司联合开发的代谢型谷氨酸受体5(mGluR5)阳性变构调节剂，通过NMDA受体发挥抗精神分裂症作用，动物实验证明ADX63356能够改善阳性症状和认知障碍 [<xref ref-type="bibr" rid="hanspub.17466-ref17">17</xref>] 。以上提示Glu 能药物可能成为新型抗精神分裂症药物研究开发的方向。</p></sec><sec id="s6_2"><title>4.2. 大麻受体</title><p>大麻受体亦属于G蛋白偶联受体家族。包括大麻1型(Cannabinoid receptor subtype 1, CB1)受体和大麻2型(Cannabinoid receptor subtype 2, CB2)受体。CB1受体分布在基底神经节、黑质、海马、苍白球、小脑等感官和运动控制区域，而这些区域与精神分裂症的发病紧密相关 [<xref ref-type="bibr" rid="hanspub.17466-ref18">18</xref>] 。Hillard等 [<xref ref-type="bibr" rid="hanspub.17466-ref19">19</xref>] 研究表明，CB1受体基因多态性与精神分裂症存在一定关系。大麻素的主要活性物质是四氢大麻酚(Δ9-Tetrahydrocannabinol, Δ9-THC)，在中枢其主要作用于CB1受体。研究表明吸食大麻会产生一系列类似于精神分裂症的症状，包括阳性症状、阴性症状和认知障碍 [<xref ref-type="bibr" rid="hanspub.17466-ref20">20</xref>] ，精神分裂症患者吸食大麻会导致症状加重。说明过度激活CB1受体与精神分裂症的发病相关。Marco等 [<xref ref-type="bibr" rid="hanspub.17466-ref21">21</xref>] 和Dalton等 [<xref ref-type="bibr" rid="hanspub.17466-ref22">22</xref>] 均报道精神分裂症患者脑内CB1受体水平的变化。且CB1 受体对与精神分裂症相关的多种神经递质如γ-氨基丁酸、谷氨酸、多巴胺、5-羟色胺等都有直接或间接的调节作用 [<xref ref-type="bibr" rid="hanspub.17466-ref23">23</xref>] 。</p><p>CBD能够部分拮抗CB<sub>1</sub>受体，在多巴胺和谷氨酸基础性精神分裂症动物模型的实验中，表现出了抗精神分裂症作用。SR141716是CB<sub>1</sub>受体拮抗剂，并具有反向激动作用。与CBD类似，SR141716在多巴胺和谷氨酸基础性精神分裂症动物模型中显示了抗精神病作用 [<xref ref-type="bibr" rid="hanspub.17466-ref24">24</xref>] 。AM251也是CB<sub>1</sub>受体拮抗剂，Zamberletti等 [<xref ref-type="bibr" rid="hanspub.17466-ref25">25</xref>] 研究证明AM251能够促进CB<sub>1</sub>受体功能恢复，改善社会隔离模型精神分裂症大鼠行为，慢性给药的效果还能持续到停药后10 d。同样AVE1625亦是一种CB<sub>1</sub>受体拮抗剂，临床前研究表明，AVE1625能够改善精神分裂症患者的认知障碍，并且与现有抗精神分裂症药物共同用药有可能会减弱后者的APS发生率 [<xref ref-type="bibr" rid="hanspub.17466-ref26">26</xref>] 。以上提示CB<sub>1</sub>受体在精神分裂症的病理学机制中发挥着重要作用，以及CB<sub>1</sub>受体拮抗剂有可能成为抗精神分裂症药物开发的新靶点。</p></sec><sec id="s6_3"><title>4.3. Sigma受体</title><p>Sigma受体由Martin等人提出。目前发现有Sigma-1和Sigma-2两个亚型，但Sigma-2受体尚未被克隆。Sigma-1受体由223个氨基酸残基组成，由内质网合成并位于内质网上，主要分布在情感调节区和脑干运动区，在黑质、海马、尾状核及扣带回等边缘系统中含量也较高 [<xref ref-type="bibr" rid="hanspub.17466-ref27">27</xref>] ，通过NMDA受体调节谷氨酸系统，参与学习、记忆，并与脑内多个神经递质系统如DA、5-HT、NE和Ach具有相互作用 [<xref ref-type="bibr" rid="hanspub.17466-ref28">28</xref>] 。</p><p>精神分裂症患者死后尸检发现与对照组相比患者脑中Sigma受体密度下降，这与重复给予苯环己哌啶(PCP)造成小鼠海马Sigma受体密度显著下降的结果相一致 [<xref ref-type="bibr" rid="hanspub.17466-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.17466-ref30">30</xref>] 。Sigma-1受体激动剂氟伏沙明、SA4503长期给药可改善PCP诱发的精神分裂症认知损害，而该改善作用可被选择性Sigma-1受体拮抗剂NE100抵消 [<xref ref-type="bibr" rid="hanspub.17466-ref31">31</xref>] 。提示Sigma受体减少可能参与PCP造成的精神分裂症认知障碍。临床双盲试验、交叉对照试验及随机对照试对Sigma-1受体激动剂治疗精神分裂症的疗效进行评估发现，氟伏沙明能改善阴性症状和认知损害，对阳性症状无改善作用，多奈哌齐、孕烯醇酮对阳性症状、阴性症状及认知损害均有不同程度的改善作用，脱氢表雄酮对阴性症状及认知损害有改善作用 [<xref ref-type="bibr" rid="hanspub.17466-ref31">31</xref>] 。以上提示，Sigma-1受体激动剂有望成为改善认知障碍的抗精神分裂症药物研发的新靶点。</p></sec></sec><sec id="s7"><title>5. 小结</title><p>药物治疗已成为精神分裂症的主要治疗方法。但是自氯丙嗪问世以来，由抗精神病药物引起的毒副反应也越来越多。虽然此后的非典型抗精神分裂症药物的锥体外系不良反应大大降低，但仍面临着临床治愈率低、复发率高以及新的不良反应。现阶段抗精神分裂症药物的研发如本文所述，由DADR和5-HTR拮抗剂，转向拮抗或部分激动DADR和5-HTR，并取得了可喜的成果，如2015年上市的卡利拉唑、依匹哌唑。此外，谷氨酸能药物，大麻受体拮抗剂，Sigma-1受体激动剂的研究也取得了一定成果。我们期望在针对相关靶点对抗精神分裂症药物研发的过程中，能够对精神分裂症的病因有更全面更深层次的认识，从而更有利于研究开发安全、有效、可控的抗精神分裂症药物。</p></sec><sec id="s8"><title>基金项目</title><p>广东省重大科技专项(2012A080201005)。</p></sec><sec id="s9"><title>文章引用</title><p>贾晓凤,何 玲. 精神分裂症治疗相关靶点及药物研究进展 Receptors and Related Drug Development for Schizophrenia: Research Advances[J]. 药物资讯, 2016, 05(02): 19-24. http://dx.doi.org/10.12677/PI.2016.52004</p></sec><sec id="s10"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.17466-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Insel, T.R. (2010) Rethinking Schizophrenia. Nature, 468, 187-193. &lt;br&gt;http://dx.doi.org/10.1038/nature09552</mixed-citation></ref><ref id="hanspub.17466-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">张立勇, 陈云芳. 抗精神病药对精神分裂症患者认知功能的影响[J]. 临床精神医学杂志, 2005, 15(1): 21-22.</mixed-citation></ref><ref id="hanspub.17466-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">汪开达. 精神药理学[M]. 北京: 人民卫生出版社, 2007.</mixed-citation></ref><ref id="hanspub.17466-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Brunetti, M., Tizio, L.D., Dezi, S., et al. (2012) Aripiprazole, Alcohol and Substance Abuse: A Review. European Review for Medical &amp; Pharmacological Sciences, 16, 1346-1354.</mixed-citation></ref><ref id="hanspub.17466-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Henderson, D.C., Fan, X.D., Copeland, P.M., et al. (2009) Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizo-phrenia Patients. Journal of Clinical Psychopharmacology, 29, 165-169. 
&lt;br&gt;http://dx.doi.org/10.1097/JCP.0b013e31819a8dbe</mixed-citation></ref><ref id="hanspub.17466-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">罗毅, 诸秉根, 杜洁. 利培酮与阿立哌唑治疗精神分裂症的疗效与安全性对比[J]. 现代仪器与医疗, 2015(6): 110-112.</mixed-citation></ref><ref id="hanspub.17466-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">马帅, 温颖玲, 周伟澄. 2015年美国FDA批准上市的新药简介[J]. 中国医药工业杂志, 2016, 47(1): 79-105.</mixed-citation></ref><ref id="hanspub.17466-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Gyertyán, I., Kiss, B., Sághy, K., et al. (2011) Cariprazine (RGH-188), a Potent D3/D2 Dopamine Receptor Partial Agonist, Binds to Dopamine D3 Receptors in Vivo and Shows An-tipsychotic-Like and Procognitive Effects in Rodents. Neurochemistry International, 59, 925-935. &lt;br&gt;http://dx.doi.org/10.1016/j.neuint.2011.07.002</mixed-citation></ref><ref id="hanspub.17466-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">赵爱玲, 赵靖平. 多巴胺和5-羟色胺受体基因多态性与抗精神病药反应[J]. 国外医学: 精神病学分册, 2002(2): 101-104.</mixed-citation></ref><ref id="hanspub.17466-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Sumiyoshi, T., Matsui, M., Nohara, S., et al. (2001) En-hancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment. American Journal of Psychiatry, 158, 1722-1725. 
&lt;br&gt;http://dx.doi.org/10.1176/appi.ajp.158.10.1722</mixed-citation></ref><ref id="hanspub.17466-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Marek, G. and Merchant, K. (2005) Developing Therapeutics for Schizophrenia and Other Psychotic Disorders. Neurorx, 2, 579-589. &lt;br&gt;http://dx.doi.org/10.1602/neurorx.2.4.579</mixed-citation></ref><ref id="hanspub.17466-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Woods, S., Clarke, N.N., Layfield, R. and Fone, K.C.F. (2012) 5-HT6 Receptor Agonists and Antagonists Enhance Learning and Memory in a Conditioned Emotion Response Paradigm by Mod-ulation of Cholinergic and Glutamatergic Mechanisms. British Journal of Pharmacology, 167, 436-449. &lt;br&gt;http://dx.doi.org/10.1111/j.1476-5381.2012.02022.x</mixed-citation></ref><ref id="hanspub.17466-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Dall’Olio, R. and Gandolfi, O. (1993) The NMDA Positive Modulator D-Cycloserine Potentiates the Neuroleptic Activity of D1 and D2 Dopamine Receptor Blockers in the Rat. Psy-chopharmacology, 110, 165-168.  
&lt;br&gt;http://dx.doi.org/10.1007/BF02246967</mixed-citation></ref><ref id="hanspub.17466-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Goff, D.C., Tsai, G., Manoach, D.S. and Coyle, JT. (1995) Dose-Finding Trial of D-Cycloserine Added to Neuroleptics for Negative Symptoms in Schizophrenia. The American Journal of Psychiatry, 152, 1213-1215.  
&lt;br&gt;http://dx.doi.org/10.1176/ajp.152.8.1213</mixed-citation></ref><ref id="hanspub.17466-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Mezler, M., Geneste, H.L. and Marek, G.J. (2010) LY-2140023, a Pro-drug of the Group II Metabotropic Glutamate Receptor Agonist LY-404039 for the Potential Treatment of Schizophrenia. Current Opinion in Investigational Drugs, 11, 833-845.</mixed-citation></ref><ref id="hanspub.17466-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kinon, B.J., Lu, Z., Millen, B.A., et al. (2011) A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients with DSM-IV Schizophrenia. Journal of Clinical Psychopharmacology, 31, 349-355. &lt;br&gt;http://dx.doi.org/10.1097/JCP.0b013e318218dcd5</mixed-citation></ref><ref id="hanspub.17466-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Fulmer, T. (2008) Schizophrenia Develops a Complex. Sci-ence-Business eXchange, 1, 5-6.  
&lt;br&gt;http://dx.doi.org/10.1038/scibx.2008.129</mixed-citation></ref><ref id="hanspub.17466-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mechoulam, R. and Parker, L.A. (2013) The Endocannabinoid System and the Brain. Annual Review of Psychology, 64, 21-47. &lt;br&gt;http://dx.doi.org/10.1146/annurev-psych-113011-143739</mixed-citation></ref><ref id="hanspub.17466-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Hillard, C.J., Weinlander, K.M. and Stuhr, K.L. (2011) Contributions of Endocannabinoid Signaling to Psychiatric Disorders in Humans: Genetic and Biochemical Evidence. Neu-roscience, 204, 207-229.  
&lt;br&gt;http://dx.doi.org/10.1016/j.neuroscience.2011.11.020</mixed-citation></ref><ref id="hanspub.17466-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sewell, R.A., Ranganathan, M. and D’Souza, D.C. (2009) Cannabinoids and Psychosis. International Review of Neurobiology, 21, 152-162. &lt;br&gt;http://dx.doi.org/10.1080/09540260902782802</mixed-citation></ref><ref id="hanspub.17466-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Marco, E.M., García-Gutiérrez, M.S., Bermúdez-Silva, F.J., Moreira, F.A., Guimarães, F., Manzanares, J. and Viveros, M.-P. (2011) Endocannabinoid System and Psychiatry: In Search of a Neurobiological Basis for Detrimental and Potential Therapeutic Effects. Frontiers in Behavioral Neuroscience, 5, 63. &lt;br&gt;http://dx.doi.org/10.3389/fnbeh.2011.00063</mixed-citation></ref><ref id="hanspub.17466-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zavitsanou, K. and Dalton, V.S. (2011) Paranoid Schizophrenia Is Characterized by Increased CB1 Receptor Binding in the Dorsolateral Prefrontal Cortex. Neuropsychopharmacology, 36, 1620-1630.  
&lt;br&gt;http://dx.doi.org/10.1038/npp.2011.43</mixed-citation></ref><ref id="hanspub.17466-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Coulston, C.M., Perdices, M., Henderson, A.F. and Malhi, G.S. (2011) Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use. Schizophrenia Research &amp; Treatment, 2011, Article ID: 50172.</mixed-citation></ref><ref id="hanspub.17466-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Roser, P., Vollenweider, F.X. and Kawohl, W. (2010) Potential Antipsychotic Properties of Central Cannabinoid (CB1) Receptor Antagonists. The World Journal of Biological Psychiatry, 11, 208-219.  
&lt;br&gt;http://dx.doi.org/10.3109/15622970801908047</mixed-citation></ref><ref id="hanspub.17466-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zamberletti, E., Viganò, D., Guidali, C., Rubino, T. and Parolaro, D. (2010) Long-Lasting Recovery of Psychotic-Like Symptoms in Isolation-Reared Rats after Chronic but Not Acute Treatment with the Cannabinoid Antagonist AM251. International Journal of Neuropsychopharmacology, 15, 267-280. &lt;br&gt;http://dx.doi.org/10.1017/S1461145710001185</mixed-citation></ref><ref id="hanspub.17466-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Black, M.D., Stevens, R.J., Rogacki, N., et al. (2010) AVE1625, a Cannabinoid CB1 Receptor Antagonist, as a Co-Treatment with Antipsychotics for Schizophrenia: Improvement in Cognitive Function and Reduction of Antipsychotic-Side Effects in Rodents. Psychopharmacology, 215, 149-163. &lt;br&gt;http://dx.doi.org/10.1007/s00213-010-2124-0</mixed-citation></ref><ref id="hanspub.17466-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Maurice, T. and Su, T.-P. (2009) The Pharmacology of Sigma-1 Receptors. Pharmacology &amp; Therapeutics, 124, 195- 206. &lt;br&gt;http://dx.doi.org/10.1016/j.pharmthera.2009.07.001</mixed-citation></ref><ref id="hanspub.17466-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Paschos, K.A., Stavroula, V. and Ekaterini, C. (2009) Neuro-peptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression. CNS Drugs, 23, 755-772.  
&lt;br&gt;http://dx.doi.org/10.2165/11310830-000000000-00000</mixed-citation></ref><ref id="hanspub.17466-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ishima, T., Fujita, Y., Kohno, M., et al. (2009) Improvement of Phencyclidine Induced Cognitive Deficits in Mice by Subsequent Subchronic Administration of Fluvoxamine, but Not Sertraline. The Open Clinical Chemistry Journal, 2, 7-11. &lt;br&gt;http://dx.doi.org/10.2174/1874241600902010007</mixed-citation></ref><ref id="hanspub.17466-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kunitachi, S., Fujita, Y., Ishima, T., Kohno, M., Horio, M., Tanibuchi, Y., Shirayama, Y., Iyo, M. and Hashimoto, K. (2014) Phencyclidine-Induced Cognitive Deficits in Mice Are Ameliorated by Subsequent Subchronic Administration of Donepezil: Role of Sigma-1 Receptors. Brain Research, 1279, 189-196.</mixed-citation></ref><ref id="hanspub.17466-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Tomihisa, N., Masaomi, I. and Kenji, H. (2012) Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases. Current Pharmaceutical Design, 18, 875-883.  
&lt;br&gt;http://dx.doi.org/10.2174/138161212799436476</mixed-citation></ref></ref-list></back></article>